KR20240002245A - Ras 저해용 조성물 및 방법 - Google Patents
Ras 저해용 조성물 및 방법 Download PDFInfo
- Publication number
- KR20240002245A KR20240002245A KR1020237031097A KR20237031097A KR20240002245A KR 20240002245 A KR20240002245 A KR 20240002245A KR 1020237031097 A KR1020237031097 A KR 1020237031097A KR 20237031097 A KR20237031097 A KR 20237031097A KR 20240002245 A KR20240002245 A KR 20240002245A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- compound
- heterocycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Lubricants (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150011P | 2021-02-16 | 2021-02-16 | |
| US63/150,011 | 2021-02-16 | ||
| US202163246181P | 2021-09-20 | 2021-09-20 | |
| US63/246,181 | 2021-09-20 | ||
| PCT/US2022/016487 WO2022177917A2 (en) | 2021-02-16 | 2022-02-15 | Compositions and methods for inhibition of ras |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240002245A true KR20240002245A (ko) | 2024-01-04 |
Family
ID=80685119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237031097A Pending KR20240002245A (ko) | 2021-02-16 | 2022-02-15 | Ras 저해용 조성물 및 방법 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240246954A1 (https=) |
| EP (1) | EP4294799A2 (https=) |
| JP (1) | JP2024508755A (https=) |
| KR (1) | KR20240002245A (https=) |
| AU (1) | AU2022224511A1 (https=) |
| BR (1) | BR112023016299A2 (https=) |
| CA (1) | CA3209083A1 (https=) |
| IL (1) | IL304986A (https=) |
| MX (1) | MX2023008463A (https=) |
| TW (1) | TW202245779A (https=) |
| WO (1) | WO2022177917A2 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| CN114867726B (zh) | 2019-10-28 | 2023-11-28 | 默沙东有限责任公司 | Kras g12c突变体的小分子抑制剂 |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| CN116368130A (zh) | 2020-08-28 | 2023-06-30 | 金橘生物科技公司 | 杂环化合物及其用途 |
| IL305568A (en) * | 2021-03-12 | 2023-10-01 | Bristol Myers Squibb Co | KRAS G12D inhibitors |
| JP2024517695A (ja) * | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | 複素環式化合物及び使用方法 |
| JP2024517693A (ja) * | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | ２－アミノベンゾチアゾール化合物及びその使用方法 |
| CN117500799A (zh) * | 2021-06-09 | 2024-02-02 | 伊莱利利公司 | 作为kras g12d抑制剂的取代的稠合吖嗪 |
| EP4373822A2 (en) * | 2021-07-23 | 2024-05-29 | Theras Inc. | Compositions and methods for inhibition of ras |
| US20240409558A1 (en) * | 2021-09-13 | 2024-12-12 | Biomea Fusion, Inc. | Irreversible inhibitors of kras |
| WO2023061294A1 (zh) * | 2021-10-13 | 2023-04-20 | 再鼎医药(上海)有限公司 | 含氮杂环类衍生物调节剂、其制备方法及应用 |
| WO2023072188A1 (zh) * | 2021-10-29 | 2023-05-04 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| WO2023103523A1 (zh) * | 2021-12-09 | 2023-06-15 | 苏州浦合医药科技有限公司 | 取代的双环杂芳基化合物作为kras g12d抑制剂 |
| WO2023114733A1 (en) * | 2021-12-13 | 2023-06-22 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| AR128212A1 (es) * | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| WO2023133183A1 (en) * | 2022-01-06 | 2023-07-13 | Theras, Inc. | Kras inhibitors |
| CN118556063A (zh) * | 2022-01-21 | 2024-08-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| MX2024008849A (es) | 2022-01-21 | 2024-07-25 | Usynova Pharmaceuticals Ltd | Compuestos de benzopirimidina y uso de estos. |
| IL314486A (en) * | 2022-02-03 | 2024-09-01 | Mirati Therapeutics Inc | Quinazoline compounds inhibit PAN-KRAS |
| AU2023218370B2 (en) | 2022-02-09 | 2024-11-28 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| EP4479398A1 (en) * | 2022-02-16 | 2024-12-25 | Amgen Inc. | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins |
| AU2023222076A1 (en) * | 2022-02-16 | 2024-08-15 | Amgen Inc. | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins |
| KR20240163107A (ko) | 2022-03-11 | 2024-11-18 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| CN118900838A (zh) * | 2022-03-24 | 2024-11-05 | 百济神州有限公司 | 杂环化合物、其组合物及其治疗方法 |
| CN116891488B (zh) * | 2022-04-11 | 2025-12-12 | 成都海博为药业有限公司 | 稠环化合物、包含其的药物组合物及应用 |
| WO2023225252A1 (en) * | 2022-05-20 | 2023-11-23 | Theras, Inc. | Compositions and methods for inhibition of ras |
| IL317601A (en) | 2022-05-25 | 2025-02-01 | Quanta Therapeutics Inc | Pyrimidine-based modulators and their uses |
| WO2023246777A1 (en) * | 2022-06-20 | 2023-12-28 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| JP2025524597A (ja) * | 2022-07-07 | 2025-07-30 | ベイジン スウィッツアランド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 複素環式化合物、その組成物、及びそれによる処置方法 |
| CA3261681A1 (en) | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| WO2024030647A1 (en) | 2022-08-05 | 2024-02-08 | Theras, Inc. | Compositions and methods for inhibition of ras |
| JP2025525938A (ja) * | 2022-08-05 | 2025-08-07 | セラス， インコーポレイテッド | Ｋｒａｓの阻害のための組成物及び方法 |
| WO2024044667A2 (en) * | 2022-08-26 | 2024-02-29 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2024063576A1 (ko) * | 2022-09-23 | 2024-03-28 | 일동제약(주) | Kras 저해 물질로서 신규한 퀴나졸린 화합물 |
| CN120077051A (zh) * | 2022-10-21 | 2025-05-30 | 苏州亚盛药业有限公司 | Kras抑制剂 |
| EP4598921A1 (en) * | 2022-11-14 | 2025-08-13 | Amgen Inc. | Macrocyclic kras inhibitors and methods of use |
| CN116554208A (zh) * | 2022-12-02 | 2023-08-08 | 苏州浦合医药科技有限公司 | 取代的双环杂芳基化合物作为kras g12d抑制剂 |
| CN116082115A (zh) * | 2023-01-06 | 2023-05-09 | 河南省科学院化学研究所有限公司 | 一种2-溴-4-氯-9,9’-二甲基芴的合成方法 |
| WO2024192424A1 (en) | 2023-03-15 | 2024-09-19 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| WO2024206747A1 (en) * | 2023-03-30 | 2024-10-03 | Eli Lilly And Company | Kras inhibitors |
| WO2024243025A1 (en) * | 2023-05-19 | 2024-11-28 | Ikena Oncology, Inc. | Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions |
| CN119219661A (zh) * | 2023-06-29 | 2024-12-31 | 西藏海思科制药有限公司 | 一种5元杂芳基衍生物及其在医药上的应用 |
| WO2025019823A1 (en) * | 2023-07-20 | 2025-01-23 | Merck Sharp & Dohme Llc | Small molecule protein degraders of kras g12d mutant |
| WO2025049402A1 (en) * | 2023-08-28 | 2025-03-06 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| WO2025051242A1 (zh) * | 2023-09-08 | 2025-03-13 | 泰励生物科技（上海）有限公司 | Ras抑制剂 |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| TW202523324A (zh) * | 2023-10-08 | 2025-06-16 | 大陸商成都海博為藥業有限公司 | 一種稠環化合物及應用 |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| AU2024357850A1 (en) | 2023-10-09 | 2026-04-23 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| WO2025085748A1 (en) | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025090811A1 (en) * | 2023-10-25 | 2025-05-01 | Kumquat Biosciences Inc. | Methods of modulating cell proliferation |
| WO2025117828A1 (en) * | 2023-12-01 | 2025-06-05 | Theras, Inc. | Compositions and methods for inhibition of ras |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10011600B2 (en) * | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| WO2017100546A1 (en) * | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| WO2017172979A1 (en) * | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| PT3735299T (pt) * | 2018-11-09 | 2024-11-25 | Hoffmann La Roche | Compostos de anéis fundidos |
| CN112110918B (zh) * | 2019-06-21 | 2023-08-22 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物，其制法与医药上的用途 |
| EP4065231A1 (en) * | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| WO2022002102A1 (en) * | 2020-06-30 | 2022-01-06 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
| CN113880827B (zh) * | 2020-07-03 | 2024-10-01 | 苏州闻天医药科技有限公司 | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 |
| US20230081426A1 (en) * | 2020-09-18 | 2023-03-16 | Plexxikon Inc. | Compounds and methods for kras modulation and indications therefor |
| US20230365563A1 (en) * | 2020-09-30 | 2023-11-16 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinazoline compound and application thereof |
-
2022
- 2022-02-15 AU AU2022224511A patent/AU2022224511A1/en active Pending
- 2022-02-15 BR BR112023016299A patent/BR112023016299A2/pt unknown
- 2022-02-15 US US18/546,317 patent/US20240246954A1/en active Pending
- 2022-02-15 CA CA3209083A patent/CA3209083A1/en active Pending
- 2022-02-15 TW TW111105463A patent/TW202245779A/zh unknown
- 2022-02-15 KR KR1020237031097A patent/KR20240002245A/ko active Pending
- 2022-02-15 JP JP2023549605A patent/JP2024508755A/ja active Pending
- 2022-02-15 MX MX2023008463A patent/MX2023008463A/es unknown
- 2022-02-15 IL IL304986A patent/IL304986A/en unknown
- 2022-02-15 EP EP22709455.4A patent/EP4294799A2/en active Pending
- 2022-02-15 WO PCT/US2022/016487 patent/WO2022177917A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022177917A2 (en) | 2022-08-25 |
| EP4294799A2 (en) | 2023-12-27 |
| WO2022177917A3 (en) | 2022-09-22 |
| US20240246954A1 (en) | 2024-07-25 |
| BR112023016299A2 (pt) | 2023-11-28 |
| JP2024508755A (ja) | 2024-02-28 |
| IL304986A (en) | 2023-10-01 |
| MX2023008463A (es) | 2023-12-07 |
| TW202245779A (zh) | 2022-12-01 |
| AU2022224511A1 (en) | 2023-08-10 |
| CA3209083A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20240002245A (ko) | Ras 저해용 조성물 및 방법 | |
| JP7050879B2 (ja) | ピラゾール化合物ならびにこの化合物を作製および使用するための方法 | |
| JP7376218B2 (ja) | Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法 | |
| TWI593683B (zh) | 雙環稠合之雜芳基或芳基化合物 | |
| US9981910B2 (en) | Substituted pyrrolidines and methods of use | |
| JP6804524B2 (ja) | Ｉｒａｋ４モジュレーターとしての二環式縮合ヘテロアリールまたはアリール化合物 | |
| TW202337466A (zh) | 用於抑制ｒａｓ之組合物及方法 | |
| EP2681215B1 (en) | Serine/threonine kinase inhibitors | |
| TW202334155A (zh) | 用於抑制ｒａｓ之組合物及方法 | |
| EP4043463B1 (en) | Fused ring derivative having mgat-2 inhibitory activity | |
| CN121843944A (zh) | 大环化合物及其抗体-药物偶联物 | |
| TW202500142A (zh) | 化合物 | |
| CN110088096A (zh) | 作为泛素特异性蛋白酶7的抑制剂的哌啶衍生物 | |
| CN110234637B (zh) | 用作irak抑制剂的吡唑酰胺化合物 | |
| TW202334141A (zh) | 作為骨髓細胞上表現之觸發受體２促效劑之雜環化合物及其使用方法 | |
| CN112135818A (zh) | 4-羟基哌啶衍生物及其作为泛素特异性蛋白酶19(usp19)的抑制剂的用途 | |
| CN117157290A (zh) | 用于抑制kras的组合物及方法 | |
| HK40104894A (zh) | 用於抑制kras的组合物及方法 | |
| HK1234395B (zh) | 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |